Tamar Ziv

Apr 8, 2024 | nature.com | Grace Goodhart |Julien Dilly |Nicole Nasholm |Tamar Ziv |Jennifer Roth |Matthew Rees | +9 more

AbstractRAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3.